Vitiligo – Current Treatment – Treatment Algorithms: Claims Data Analysis – Vitiligo (US)
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or functional loss of melanocytes. Given its visible manifestations, the disease is associated with a substantial patient burden. Until recently, no therapies were specifically approved for vitiligo; management relied primarily on topical corticosteroids or other immunomodulators, used alone or in combination with narrow-band UVB to induce repigmentation. However, these approaches often provide only modest and variable clinical benefits and may be associated with treatment-related adverse effects. In July 2022, the FDA approved Incyte’s Opzelura (topical ruxolitinib) as the first pharmacologic treatment indicated for repigmentation in adult and pediatric patients aged 12 years and older with nonsegmental vitiligo. Our Treatment Algorithms study leverages national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for vitiligo.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed vitiligo patients?
- How has Opzelura been integrated into the treatment algorithm, and what is its source of business?
- What percentage of vitiligo patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What are the product-level compliance and persistency rates among drug-treated patients?
Content highlights
Geography: United States
Real-world data: U.S. pharmacy and medical claims data
Key drugs covered: Opzelura, key topical corticosteroids, and calcineurin inhibitors
Key analyses:
Brand / therapy usage across longitudinal patient sample
Newly diagnosed patient analysis
Treatment initiation and progression
Line of therapy analysis
Combination therapy analysis
Source of business for recently treated patients
Persistency and compliance analysis
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
